ExCellThera

Focus: ExCellThera is a Montreal-based biotechnology company founded in 2023 specializing in growing blood stem cells for therapeutic use, currently in early-stage clinical development with a focus on cell therapy for hematologic malignancies.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About ExCellThera

AI assessmentNot Hiring

No open roles listed right now. Follow ExCellThera to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ECT-001-CB

Sickle Cell Disease

PHASE_1

Clinical Trials (1)

NCT04594031US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

Phase 1

Help build intelligence for ExCellThera

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public cell therapy company with proprietary stem cell expansion technology targeting high-value indications (multiple myeloma, sickle cell disease)
Portfolio spans both hematologic malignancies and genetic blood disorders, offering exposure to multiple therapeutic pathways with significant unmet need
Montreal biotech hub location with emerging cell therapy ecosystem and early-stage equity upside potential

Watch Out For

Zero active job openings despite public status signals minimal hiring or potential recruitment freeze at early stage
No revenue, published clinical data, or FDA milestones available; company is entirely pre-revenue and early-stage with execution risk

Generated by Claude from ExCellThera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ECT-001-CB

High Risk Myeloid Malignancies

PHASE_1_2

Clinical Trials (1)

NCT04990323US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Phase 1/2

ECT-001

Multiple Myeloma

PHASE_1_2

Clinical Trials (1)

NCT03441958ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Phase 1/2

Transplant with an expanded ECT-001 cord blood

High Risk Hematologic Malignancy

PHASE_2

Clinical Trials (1)

NCT03913026UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

Phase 2

ECT-001-CB

High Risk Hematological Malignancy

PHASE_2

Clinical Trials (1)

NCT04103879US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

Phase 2

Therapeutic Inducers of Natural Killer Killing

Leukaemia (Acute Lymphoblastic)

Phase 1

Clinical Trials (1)

NCT07518654Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma

Phase 1